All In Biotech

Drug Trial Radar · NCT05659953

LMT503 First-in-human SAD, MAD, and FE Study

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LMT503 in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Mar 1, 2027

Primary completion

Sep 1, 2027

Study completion Dec 1, 2027

Sponsor

Lead sponsor
Lmito Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Dec 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, placebo-controlled study, consisting of a single ascending dose (SAD) part with integrated food effect (FE) arm, and a multiple ascending dose (MAD) part to assess the safety, tolerability, and PK of ascending single and multiple oral doses of LMT503. The study will start with the SAD part.

Conditions

  • Inflammatory Bowel Disease
  • Colitis, Ulcerative
  • Crohn Disease

Interventions

  • LMT503Drug

    Subjects will receive one of several different oral doses of LMT503 once daily

  • PlaceboDrug

    Subjects will receive one of several different oral doses of Placebo once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Treatment Emergent Adverse Events (TEAEs) in the SAD and MAD partTime frame: up to Day 17

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON plc Company - Early Development Services

    Groningen, NZ, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.